AbbVie: Hypogonadism trials

The registry lists 25 Hypogonadism studies with AbbVie as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 5Phase 2 7Phase 3 10Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male ParticipantsCompletedNCT04320745Phase 4Results posted
• A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With HypogonadismCompletedNCT04274894Phase 4Results posted
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal MenCompletedNCT03518034Phase 4Results posted
• A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg EnclomipheneCompletedNCT02651688Phase 2Results posted
• Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary HypogonadismCompletedNCT01739595Phase 3Results posted
• Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary HypogonadismCompletedNCT01534208Phase 3Results posted
• Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary HypogonadismCompletedNCT01532414Phase 3Results posted
• The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)CompletedNCT01386606Phase 2Results posted
• Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal SystemsCompletedNCT01323140Phase 2Results posted
• Normalization of Morning Testosterone Levels in Men With Secondary HypogonadismCompletedNCT01270841Phase 2Results posted
• Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes MellitusCompletedNCT01191320Phase 2Results posted
• Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal MenCompletedNCT01104246Phase 1Results posted
• To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical TestosteroneCompletedNCT00706719Phase 2Results posted
• An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral AdministrationCompletedNCT02274181Phase 1
• An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal MenWithdrawnNCT02082197Phase 3
• A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%CompletedNCT01993225Phase 3
• A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%CompletedNCT01993212Phase 3
• Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic FunctionCompletedNCT01923870Phase 1
• Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal FunctionCompletedNCT01923857Phase 1
• An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary HypogonadismCompletedNCT01739582Phase 3
• Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary HypogonadismCompletedNCT01619683Phase 3
• A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203CompletedNCT01386567Phase 2
• Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal MalesCompletedNCT01133548Phase 1
• Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary HypogonadismCompletedNCT01067365Phase 3
• Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary HypogonadismCompletedNCT00962637Phase 3